This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 26 November 2021. Bharat Biotech's new vaccine COVAXIN/ BBV152 received WHO EUL authorisation on 3 November 2021 leading to seven vaccines being now authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), Sinovac/CoronaVac (China), and COVAXIN/BBV152 (Bharat Biotech, India)]. This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and observational studies. This report focuses on the latest data on vaccine effectiveness, vaccine induced immunity, breakthrough infections, and booster doses.